| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285
Published, JLR Papers in Press, December 3, 2007.
1 To whom correspondence should be addressed. e-mail: konrad_robert{at}lilly.com
Preβ1 HDL is the initial plasma acceptor of cell-derived cholesterol in reverse cholesterol transport. Recently, small amphipathic peptides composed of D-amino acids have been shown to mimic apolipoprotein A-I (apoA-I) as a precursor for HDL formation. ApoA-I mimetic peptides have been proposed to stimulate the formation of preβ1 HDL and increase reverse cholesterol transport in apoE-null mice. The existence of a monoclonal antibody (MAb 55201) and a corresponding ELISA method that is selective for the detection of the preβ1 subclass of HDL provides a means of establishing a correlation between apoA-I mimetic dose and preβ1 HDL formation in human plasma. Using this preβ1 HDL ELISA, we demonstrate marked apoA-I mimetic dose-dependent preβ1 HDL formation in human plasma. These results correlated with increases in band density of the plasma preβ1 HDL, when observed by Western blotting, as a function of increased apoA-I mimetic concentration. Increased preβ1 HDL formation was observed after as little as 1 min and was maximal within 1 h. Together, these data suggest that a high-throughput preβ1 HDL ELISA provides a way to quantitatively measure a key component of the reverse cholesterol transport pathway in human plasma, thus providing a possible method for the identification of apoA-I mimetic molecules.
Supplementary key words high density lipoprotein • cholesterol • reverse cholesterol transport
Abbreviations: apoA-I, apolipoprotein A-I; PK, pharmacokinetic
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Journal of Biological Chemistry |
| Molecular and Cellular Proteomics | ASBMB Today |
